Regentis Biomaterials Ltd. (RGNT)

Regentis Biomaterials Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025
Period Ending	Dec 31, 2025
Cash & Equivalents	7.38
Cash & Short-Term Investments	7.38
Other Current Assets	0.24
Total Current Assets	7.62
Total Assets	7.62
Accounts Payable	0.27
Accrued Expenses	1.41
Short-Term Debt	1.2
Total Current Liabilities	2.87
Total Liabilities	2.87
Shareholders' Equity	4.74
Total Liabilities & Equity	7.62
Total Debt	1.2
Net Cash (Debt)	6.18
Net Cash Per Share	10.91
Book Value	4.74
Book Value Per Share	8.37
Tangible Book Value	4.74
Tangible Book Value Per Share	8.37

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q